Phase 2 trial in 62 patients with high-risk HPV-positive oropharyngeal cancer: induction nivolumab before chemoradiation failed its feasibility endpoint (4/41 got <200 mg/m2 cisplatin); grade 4-5 adverse events occurred only with nivolumab (7 patients).
RCTn = 62
Mirghani et al. Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial